Rubius Therapeutics, Inc.
(NASDAQ : RUBY)

( )
RUBY PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
REGNRegeneron Pharmaceuticals, Inc. -1.85%731.862.6%$754.70m
AMGNAmgen, Inc. -1.23%230.941.4%$608.51m
MRNAModerna, Inc. -0.37%125.150.0%$589.94m
BIIBBiogen, Inc. 0.22%262.261.8%$580.04m
GILDGilead Sciences, Inc. -0.76%64.951.0%$550.05m
VRTXVertex Pharmaceuticals, Inc. -1.12%298.631.9%$429.92m
ILMNIllumina, Inc. -2.65%212.723.2%$410.84m
SNSSSunesis Pharmaceuticals, Inc. -1.47%4.020.7%$281.01m
SAVACassava Sciences, Inc. 3.37%42.350.0%$189.68m
BNTXBioNTech SE 0.25%137.530.0%$109.40m
TECHBio-Techne Corp. 0.17%309.084.5%$100.77m
BMRNBioMarin Pharmaceutical, Inc. 2.18%91.484.2%$95.92m
NVAXNovavax, Inc. -3.32%18.0875.6%$79.49m
PRTAProthena Corp. Plc 0.79%58.5713.8%$79.21m
SNTISenti Biosciences, Inc. 23.49%6.520.0%$78.99m

Company Profile

Rubius Therapeutics, Inc. engages in the development of red-cell therapeutic medicines for cancer, autoimmune diseases, hemophilia, and infectious and metabolic diseases. The company was founded by Avak Kahvejian, Jordi Mata-Fink, and Noubar Afeyan on April 26, 2013 and is headquartered in Cambridge, MA.